Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

The structure-based design, chemical synthesis, and biological evaluation of bicyclic 2-pyridone-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. An optimized compound is shown to exhibit antiviral activity when tested against a variety of HRV serotypes (EC(50)'s ranging from 0.037 to 0.162 microM).

[1]  M Kahn,et al.  Concepts and progress in the development of peptide mimetics. , 1993, Journal of medicinal chemistry.

[2]  Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. , 1996, Journal of medicinal chemistry.

[3]  V. Garsky,et al.  Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. , 1990, The Journal of biological chemistry.

[4]  J. Palmer,et al.  Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.

[5]  D. Rich,et al.  Measurement of individual rate constants of irreversible inhibition of a cysteine proteinase by an epoxysuccinyl inhibitor , 1995 .

[6]  P. Dragovich,et al.  Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides. , 1999, Bioorganic & medicinal chemistry.

[7]  Kazuki Sato,et al.  Bicyclic turned dipeptide (BTD) as a β-turn mimetic; its design, synthesis and incorporation into bioactive peptides , 1993 .

[8]  D. Matthews,et al.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Dunn,et al.  Hydrolysis of a series of synthetic peptide substrates by the human rhinovirus 14 3C proteinase, cloned and expressed in Escherichia coli. , 1989, The Journal of general virology.

[10]  Mary E. McGrath,et al.  Crystal structure of human cathepsin K complexed with a potent inhibitor , 1997, Nature Structural Biology.

[11]  Michael G. C. Kahn.  Peptide Secondary Structure Mimetics: Recent Advances and Future Challenges , 1993 .

[12]  Thomas Kolter,et al.  Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives , 1993 .

[13]  V J Hruby,et al.  Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. , 2000, Current medicinal chemistry.

[14]  V. Garsky,et al.  Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli , 1989, Journal of virology.

[15]  R. Hanzlik,et al.  Structure-activity relationships for inhibition of papain by peptide Michael acceptors. , 1992, Journal of medicinal chemistry.

[16]  J. DiMaio,et al.  Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications. , 1998, Bioorganic & medicinal chemistry letters.

[17]  L. Stanberry,et al.  Preface to the fifth edition , 2014 .

[18]  D. Matthews,et al.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. , 1999, Journal of medicinal chemistry.

[19]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[20]  S. Hanessian,et al.  Exploring the chiral space within the active site of alpha-thrombin with a constrained mimic of D-Phe-Pro-Arg--design, synthesis, inhibitory activity, and X-ray structure of an enzyme-inhibitor complex. , 2000, Bioorganic & medicinal chemistry letters.

[21]  R. Fletterick,et al.  Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: structural and functional implications. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Marc Allaire,et al.  Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases , 1994, Nature.

[23]  P. Dragovich.  Recent advances in the development of human rhinovirus 3C protease inhibitors , 2001 .

[24]  J. Palmer,et al.  Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. , 1996, The Biochemical journal.

[25]  S. L. Gwaltney,et al.  Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases , 1998 .

[26]  R. Hanzlik,et al.  Vinylogous amino acid esters: a new class of inactivators for thiol proteases. , 1984, Journal of medicinal chemistry.

[27]  J. Gante,et al.  Peptidomimetics—Tailored Enzyme Inhibitors† , 1994 .

[28]  J. P. Shea,et al.  Secondary structure peptide mimetics: design, synthesis, and evaluation of beta-strand mimetic thrombin inhibitors. , 1999, Journal of medicinal chemistry.

[29]  D. Matthews,et al.  Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. , 1998, Journal of medicinal chemistry.

[30]  V. Blinov,et al.  Poliovirus‐encoded proteinase 3C: a possible evolutionary link between cellular serine and cysteine proteinase families , 1986, FEBS letters.

[31]  D. Matthews,et al.  Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein , 1994, Cell.

[32]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[33]  J. Tao,et al.  An efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor AG7088 via asymmetric dianionic cyanomethylation of N-Boc-l-(+)-glutamic acid dimethyl ester , 2001 .

[34]  J. DiMaio,et al.  Synthesis and structure-activity relationship of potent bicyclic lactam thrombin inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[35]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .